World Patient Safety Summit Aims to Reduce Unnecessary C-Sections
Two survivors of C-section delivery and postpartum complications will be part of a distinguished panel at the upcoming 2018 World Patient Safety Science & Technology Summit in London, on Saturday, February 24.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180213006342/en/
Kristen Terlizzi will share her near-fatal experience of postpartum care at the 6th Annual World Patient Safety, Science & Technology Summit in London, UK. (Photo: Business Wire)
According to researchers, C-sections or deliveries of newborns by caesarean section, is on the rise but nearly half of those cases are unnecessary and complications from the procedure are not well known or understood. The Patient Safety Movement Foundation is pleased to announce the panelists participating in the upcoming Reducing Unnecessary C-Sections in Hospitals Panel. These include Jill Arnold and Kristen Terlizzi who have become fierce patient advocates since their near fatal experiences in delivering their infants by C-section and the complications that followed.
The Statistics: Internationally, C-sections are on the rise ranging from an average of 40.5% in Latin America/Caribbean area to 7.3% in Africa (Betran 2016). In the United States, one-third of patients give birth surgically (Martin, 2017) and international experts have identified this high cesarean rate as a significant maternal health safety issue (Council on Patient Safety in Women’s Health Care 2016).
Kristen Terlizzi’s post-partum medical care was so extreme, it inspired a scientific journal case study. An earlier C-section left her with a condition called Placenta Accreta – where placental tissue remains and spreads affecting other organs. Hemorrhaging during corrective surgery was so acute, she had her entire blood supply replaced.
Jill Arnold was the picture of health and breezed through a low-risk pregnancy and delivery but the lack of emphasis on postpartum care in the U.S. left her at risk. She began showing symptoms of DVT – Deep Vein Thrombosis – which could have easily killed her. “A leg-length clot had developed in a superficial vein that extended from my ankle all the way up to the groin,” said Arnold.
Unnecessary C-sections also pose long-term health risks including subsequent uterine scar rupture, abnormal placentation, increased risk of hemorrhage, and hysterectomy (Bauserman 2015, Marshall 2011, Rageth 1999, Galyean 2009) where there is an exponential increase in such complications with the number of prior cesareans (Clark 1985).
The Reducing Unnecessary C-sections panel will discuss best practices from around the world and announce the new Actionable Patient Safety Solutions related to this topic.
Members of the Global Panel include:
- Moderator: David C. Lagrew Jr., MD, Executive Medical Director of Women’s Service, St. Joseph-Hoag Health Region of Providence Healthcare – Dr. Lagrew is a maternal fetal medicine specialist and physician informaticist with a special interest in maternal quality improvement. He has helped develop and pioneer techniques in cesarean section reduction, emergent cesarean section drills, and maternal quality improvement in techniques.
- Kristen Terlizzi, Co-founder, National Accreta Foundation – Ms. Terlizzi now shares her patient story to educate audiences on abnormal placentation and the downstream costs of cesarean deliveries. Her medical case report is published in the official journal of the American Congress of Obstetricians and Gynecologists (ACOG) and her patient story has been featured in Vox Media, the Wall Street Journal and People.com.
- Jill Arnold, Co-founder, National Accreta Foundation - Jill Arnold’s research on C-section, VBAC and other delivery method data led to the creation of a registry of national hospital-level data that Consumer Reports licensed in 2013. Jill currently serves as the Vice Chair of the Arkansas Healthcare Transparency Initiative Task Force Board, is an Editorial Board Member of the Institute for Perinatal Quality Improvement and an Expert Consultant to the Delivery Decisions Initiative at Harvard’s Ariadne Labs as well as serving as a member of the steering committee of the California Maternal Quality Care Collaborative (CMQCC) Maternal Data Center since 2013.
- Siddarth Satish, Founder, Chief Executive Officer, Gauss Surgical - Siddarth Satish is the Founder and CEO of Gauss Surgical, a medical technology company using computer vision and machine learning to make surgery and childbirth safer and more cost-effective. He serves on the Technology Committee of the Anesthesia Patient Safety Foundation, and was named to the Forbes 30 Under 30 list in healthcare.
- Robert M. Silver, MD, Professor of Obstetrics and Gynecology, University of Utah Health Sciences Center – Dr. Silver joined the University of Utah Maternal-Fetal Medicine Division after completing his fellowship there in 1994. He is serving as the Chief of the Division of Maternal-Fetal Medicine and as Co-Director of Labor and Delivery at the UUHSC.
For more information, please visit the Patient Safety Movement Foundation website. Members of the media may request a press pass by visiting http://bit.ly/2mCeyay or by contacting Tanya Lyon – phone (949) 351-2858 or email firstname.lastname@example.org.
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, (949) 351-2858
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00 | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00 | Tiedote
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26 | Tiedote
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05 | Tiedote
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03 | Tiedote
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 11:00 | Tiedote
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme